Integral Health Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Integral Health Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$5.02M	–	93
2025 Q4	$5.02M	Sell	200,000 -50,000	-20%	-$1.17M	0.25%	70
2025 Q3	$5.66M	Buy	+250,000	New	+$5.83M	0.38%	68
2025 Q1	–	Sell	-420,000	Closed	-$13.4M	–	83
2024 Q4	$13.4M	Buy	+420,000	New	+$12.6M	1.14%	32
2024 Q2	–	Sell	-150,000	Closed	-$8.82M	–	78
2024 Q1	$8.82M	Buy	+150,000	New	+$9.56M	0.82%	49
2023 Q3	–	Sell	-72,000	Closed	-$6.56M	–	69
2023 Q2	$6.56M	Buy	+72,000	New	+$6.21M	0.81%	47
2022 Q4	–	Sell	-70,000	Closed	-$4.78M	–	65
2022 Q3	$4.78M	Sell	70,000 -29,150	-29%	-$1.72M	0.93%	43
2022 Q2	$4.48M	Buy	99,150 +59,381	+149%	+$2.71M	0.92%	36
2022 Q1	$2.02M	Sell	39,769 -80,231	-67%	-$3.54M	0.53%	56
2021 Q4	$5.67M	Sell	120,000 -70,000	-37%	-$2.76M	1.57%	27
2021 Q3	$6.26M	Buy	190,000 +155,000	+443%	+$8.71M	1.8%	18
2021 Q2	$2.21M	Buy	+35,000	New	+$1.81M	0.61%	47
2020 Q4	–	Sell	-90,000	Closed	-$2.71M	–	58
2020 Q3	$2.71M	Buy	+90,000	New	+$2.69M	0.83%	45
2020 Q1	–	Sell	-35,000	Closed	-$1.07M	–	56
2019 Q4	$1.07M	Buy	+35,000	New	+$969K	0.42%	48

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Integral Health Asset Management's APLS Position: Q1 2026 in Review

Integral Health Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 200,000 shares — an estimated $5.02M sold.

Integral Health Asset Management first reported a position in APLS in Q4 2019 and held it in 13 quarters. The position peaked at $13.4M in Q4 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Integral Health Asset Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Integral Health Asset Management sold 200,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.02M.
Integral Health Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 13 quarters.
Integral Health Asset Management's Apellis Pharmaceuticals position peaked at $13.4M in Q4 2024.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.